Last reviewed · How we verify
Sunitinib malate capsules reference product — Competitive Intelligence Brief
Target snapshot
Sunitinib malate capsules reference product (Sunitinib malate capsules reference product) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Multi-targeted receptor tyrosine kinase inhibitor that blocks VEGFR, PDGFR, KIT, FLT3, and RET signaling pathways involved in tumor growth and angiogenesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sunitinib malate capsules reference product TARGET | Sunitinib malate capsules reference product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sunitinib malate capsules reference product CI watch — RSS
- Sunitinib malate capsules reference product CI watch — Atom
- Sunitinib malate capsules reference product CI watch — JSON
- Sunitinib malate capsules reference product alone — RSS
Cite this brief
Drug Landscape (2026). Sunitinib malate capsules reference product — Competitive Intelligence Brief. https://druglandscape.com/ci/sunitinib-malate-capsules-reference-product. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing